Millie Long, MD, MPH

Vice Chief of Education, Fellowship Program Director

Division of Gastroenterology and Hepatology at UNC Health Care

Chapel Hill, NC

Articles by Millie Long, MD, MPH

Risankizumab Subcutaneous Induction for Crohn’s Disease: Insights From the AFFIRM Trial, With Millie Long, MD, MPH

March 11th 2026

Long discusses AFFIRM data showing strong clinical and endoscopic outcomes with SC risankizumab (Skyrizi) induction in Crohn’s disease.

Key Takeaways and Prospective Treatment Advances

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

July 26th 2023

David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long summarize their discussion of Inflammatory Bowel Disease (IBD) and discuss prospective advances in treatment options.

Biosimilar Treatment Options for Patients With UC

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

July 26th 2023

Experts discuss the recent use of biosimilars like inolimomab as treatment for ulcerative colitis (UC).

Treatment Sequencing for UC

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

July 19th 2023

Experts offer clinical advice on therapy sequencing of Janus kinase (JAK) inhibitors for ulcerative colitis (UC) and when surgery may be appropriate.

Utilizing JAK Inhibitors in Patients With UC

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

July 19th 2023

Experts discuss how they utilize Janus kinase (JAK) inhibitors for patients with ulcerative colitis (UC).

The Role of Ustekinumab in UC

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

July 12th 2023

Millie Long, David Hudesman, MD, Maia Kayal, MD, and Miguel Regueiro, MD, discuss treatment strategies for ulcerative colitis (UC) utilizing ustekinumab.

The Role of Ozanimod in UC

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

July 12th 2023

Miguel Regueiro, MD, discusses the role of ozanimod as a treatment option for ulcerative colitis (UC).

Treatment Approaches for Patients With UC

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

July 5th 2023

Anita Afzali, MD, discusses treatment approaches to ulcerative colitis (UC) and how they may differ from Crohn’s Disease (CD).

Major Takeaways for Treating CD

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

July 5th 2023

Experts summarize their clinical strategies for monitoring and treating patients with Crohn’s Disease (CD).

Optimizing Therapies for CD

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

June 28th 2023

Millie Long, Miguel Regueiro, MD, Maia Kayal, MD, Anita Afzali, MD, and David Hudesman, MD, offer clinical strategies for optimizing treatments for Crohn’s Disease (CD) patients.

Second-Line Therapies for CD

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

June 28th 2023

Miguel Regueiro, MD, offers his clinical advice on second-line therapies for patients with Crohn’s Disease (CD).

Experts discuss inflammatory bowel diseases.

Selecting Treatments in Patients With EIM

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

June 21st 2023

Anita Afzali, MD, David Hudesman, MD, and Maia Kayal, MD, discuss how extra intestinal manifestations (EIM) affect therapy strategies for Crohn’s Disease (CD) patients.

Selecting Therapies for CD in Pregnancy

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

June 21st 2023

Millie Long discusses treatment considerations for Crohn’s Disease (CD) patients who are planning for pregnancy.

Efficacy and Safety of Ustekinumab for CD

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

June 14th 2023

Experts discuss the results of a five-year efficacy and safety trial of ustekinumab for treatment of Crohn’s Disease (CD).

The Role of Vedolizumab and Risankizumab in CD

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

June 14th 2023

Anita Afzali, MD, David Hudesman, MD, Millie Long, and Miguel Regueiro, MD, discuss Vedolizumab and Risankizumab as treatments for Crohn’s Disease (CD).

Selecting First-Line Treatments for CD

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

June 7th 2023

David Hudesman, MD, Miguel Regueiro, MD, and Maia Kayal, MD, offer first line treatment strategies for patients with Crohn’s Disease (CD).

Managing Care for IBD Patients Not Responding to Treatment

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

June 7th 2023

Experts discuss how to care for Inflammatory Bowel Disease (IBD) patients who are not responding to treatment.

Treatment Factors of IBD

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

May 31st 2023

Experts discuss treatment options for patients with Inflammatory Bowel Disease (IBD) and clinical factors to consider.

Overview of IBD

ByDavid P. Hudesman, MD,Maia Kayal, MD,Miguel Regueiro, MD,Anita Afzali, MD,Millie Long, MD, MPH

May 31st 2023

David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long discuss the current treatment landscape for Inflammatory Bowel Disease (IBD).